Skip To Main Content
Protalix BioTherapeutics on Muck Rack

Protalix BioTherapeutics

As seen in: Yahoo Finance, Associated Press, Associated Press: Press Releases, PR Newswire, AU Investing, Investing Canada, Investing.com, KTLA-TV (Los Angeles, CA), KDVR-TV (Denver, CO), StreetInsider and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Protalix BioTherapeutics’s profile

Articles by Protalix BioTherapeutics

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

|
By Protalix BioTherapeutics, Stockholders' Equity, Development Expenses
| Stockwatch
Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment Year-to-date, the Company achieved profitability with a net income of $22.1...
Open in Who Shared View Duplicates (44) Issue with article?
|
By Protalix BioTherapeutics
| chase.com
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results 6:50 AM EDT 5/13/2026 - Comtex CARMIEL, Israel, May 13, 2026 /PRNewswire via COMTEX News Network/ -- Company to host conference call and webcast today at 8:00 a.m. EDT -- Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every-4-weeks (E4W) dosing regimen; $25 million milestone received from Chiesi -- PRX-115 Phase 2 study continues to advance as planned with top-line...
Open in Who Shared View Duplicates (68) Issue with article?
|
By Protalix BioTherapeutics
| chase.com
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results 6:50 AM EDT 3/18/2026 - Comtex CARMIEL, Israel, March 18, 2026 /PRNewswire via COMTEX News Network/ -- Company to host conference call and webcast today at 8:00 a.m. EDT -- The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio in adults living with Fabry disease providing a meaningful reduction in treatment burden without compromising efficacy -- The EC approval...
Open in Who Shared View Duplicates (71) Issue with article?
|
By Protalix BioTherapeutics
| chase.com
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results 6:50 AM EST 11/13/2025 - Comtex CARMIEL, Israel, Nov. 13, 2025 /PRNewswire via COMTEX News Network/ -- Company to host conference call and webcast today at 8:00 a.m. EST Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (101) Issue with article?

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

|
By Protalix BioTherapeutics
| Yahoo Finance Verified
Chiesi Global Rare Diseases; Protalix Biotherapeutics Every two weeks remains approved as a dosing regimen of Elfabrio in the EU PARMA, Italy and CARMIEL, Israel, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (101) Issue with article?

Protalix BioTherapeutics to Present at Investor Summit Virtual

|
By Protalix BioTherapeutics
| ACCESS Newswire
CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (35) Issue with article?
|
By Protalix BioTherapeutics
| chase.com
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results 6:50 AM EDT 8/14/2025 - Comtex CARMIEL, Israel, Aug. 14, 2025 /PRNewswire via COMTEX News Network/ -- Company to host conference call and webcast today at 8:30 a.m. EDT Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (67) Issue with article?
|
By Protalix BioTherapeutics
| Kilgore News Herald Verified
Open in Who Shared Issue with article?

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

|
By Protalix BioTherapeutics
| WV News Verified
, /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the Company has been added to the Russell 3000® and Russell 2000® Indexes, effective as of the U.S. market close on June 27, 2025, as part of the 2025 Russell indexes annual reconstitution.
Open in Who Shared View Duplicates (99) Issue with article?
|
By Protalix BioTherapeutics
| chase.com
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results 6:50 AM EDT 5/09/2025 - Comtex CARMIEL, Israel, May 9, 2025 /PRNewswire via COMTEX News Network/ -- Company to host conference call and webcast today at 8:30 a.m. EDT Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (96) Issue with article?

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

|
By Protalix BioTherapeutics
| Longview News-Journal Verified
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (12) Issue with article?

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

|
By Protalix BioTherapeutics
| Longview News-Journal Verified
CARMIEL, Israel, March 24, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that its management will be participating in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, to be held virtually March 25-26, 2025.
Open in Who Shared View Duplicates (85) Issue with article?
|
By Protalix BioTherapeutics
| chase.com
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results 6:50 AM EDT 3/17/2025 - Comtex CARMIEL, Israel, March 17, 2025 /PRNewswire via COMTEX News Network/ -- Company to host conference call and webcast today at 8:30 a.m. EDT Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (104) Issue with article?

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

|
By Protalix BioTherapeutics
| WKRG-TV (Mobile, AL) Verified
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 10, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (79) Issue with article?

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

|
By Protalix BioTherapeutics
| KHON-TV (Honolulu, HI) Verified
Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST , /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared Issue with article?

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

|
By Protalix BioTherapeutics
| WKBN-TV (Youngstown, OH) Verified
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST , /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (84) Issue with article?

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

|
By Protalix BioTherapeutics
| WV News Verified
Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST , /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared Issue with article?

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

|
By Protalix BioTherapeutics
| PR Newswire UK
- Application to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every four weeks in adult patients with Fabry disease in European Union , /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (150) Issue with article?

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

|
By Protalix BioTherapeutics
| Investing.com
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EST , /PRNewswire/ --  Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (120) Issue with article?

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

|
By Protalix BioTherapeutics
| WNCN-TV (Raleigh, NC) Verified
Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update.
Open in Who Shared Issue with article?

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

|
By Protalix BioTherapeutics
| Chicago Star Media Verified
Company to host conference call and webcast at 8:30 a.m. EST , /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (13) Issue with article?

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

|
By Protalix BioTherapeutics
| WGN-TV (Chicago, IL) Verified
CARMIEL, Israel, Oct. 25, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (133) Issue with article?

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

|
By Protalix BioTherapeutics
| Longview News-Journal Verified
CARMIEL, Israel , /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (3) Issue with article?

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

|
By Protalix BioTherapeutics
| KTVI-TV (St. Louis, MO) Verified
CARMIEL, Israel, Sept. 4, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (74) Issue with article?

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

|
By Protalix BioTherapeutics
| KSNT-TV (Topeka, KS) Verified
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference , /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared Issue with article?

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

|
By Protalix BioTherapeutics
| WTVO-TV (Rockford, IL) Verified
, /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (6) Issue with article?

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes

|
By Protalix BioTherapeutics
| KTVI-TV (St. Louis, MO) Verified
Company is debt-free with no outstanding notes Balance sheet provides sufficient runway for ongoing operations CARMIEL, Israel, Sept. 3, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (116) Issue with article?
|
By Protalix BioTherapeutics
| chase.com
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results 6:50 AM EDT 8/14/2024 - Comtex CARMIEL, Israel, Aug. 14, 2024 /PRNewswire via COMTEX News Network/ -- Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2024 /PRNewswire/--Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (112) Issue with article?

Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

|
By Protalix BioTherapeutics
| KSNT-TV (Topeka, KS) Verified
Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 Company to host conference call and webcast at 8:30 a.m. EDT , /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (72) Issue with article?

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

|
By Protalix BioTherapeutics
| KDVR-TV (Denver, CO) Verified
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout Event will take place on Wednesday, June 26, 2024 in New York , /PRNewswire/ -- Protalix BioTherapeutics, Inc.
Open in Who Shared View Duplicates (196) Issue with article?
Show More